1. Home
  2. REGN vs MDLZ Comparison

REGN vs MDLZ Comparison

Compare REGN & MDLZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$699.02

Market Cap

77.5B

Sector

Health Care

ML Signal

HOLD

Logo Mondelez International Inc.

MDLZ

Mondelez International Inc.

HOLD

Current Price

$60.42

Market Cap

70.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGN
MDLZ
Founded
1988
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Packaged Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
77.5B
70.5B
IPO Year
1995
2001

Fundamental Metrics

Financial Performance
Metric
REGN
MDLZ
Price
$699.02
$60.42
Analyst Decision
Buy
Buy
Analyst Count
25
20
Target Price
$830.16
$66.95
AVG Volume (30 Days)
695.9K
6.9M
Earning Date
04-29-2026
04-28-2026
Dividend Yield
0.55%
3.28%
EPS Growth
8.19
N/A
EPS
6.75
0.44
Revenue
$5,872,227,000.00
$38,537,000,000.00
Revenue This Year
$12.45
$4.83
Revenue Next Year
$10.13
$3.10
P/E Ratio
$105.86
$138.36
Revenue Growth
20.82
5.75
52 Week Low
$476.49
$51.20
52 Week High
$821.11
$71.15

Technical Indicators

Market Signals
Indicator
REGN
MDLZ
Relative Strength Index (RSI) 39.31 54.19
Support Level $679.36 $60.32
Resistance Level $783.87 $62.60
Average True Range (ATR) 19.66 1.18
MACD 0.06 -0.03
Stochastic Oscillator 34.75 61.90

Price Performance

Historical Comparison
REGN
MDLZ

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About MDLZ Mondelez International Inc.

Mondelez has operated independently since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (49% of sales as of the end of fiscal 2024), chocolate (31%), gum/candy (11%), beverage (3%), and cheese and grocery (6%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury. The firm derives around one-third of its revenue from developing markets, more than one-third from Europe, and the remainder from North America.

Share on Social Networks: